SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS

1 . A compound of Formula (I)

wherein:

X 1 is selected from the group consisting of CH 2 and C 2-4 alkylene substituted with from 0 to 1 —OH;

ring A is selected from the group consisting of phenyl and a 5- to 10-membered heteroaryl having 1 to 4 heteroatoms as ring vertices independently selected from N, O, and S;

the subscripts m and n are each independently 0 or 1;

R 1 and R 2 , when present, are each independently selected from the group consisting of C 1-4 alkyl, C 1-4 alkoxy, halo, C 1-4 haloalkyl, C 1-4 haloalkoxy, C 1-4 hydroxyalkyl, —X a —O—C 1-4 alkyl, —C(O)OH, and cyano, wherein X a is independently selected from a bond and C 1-4 alkylene;

Ar 1 is selected from the group consisting of phenyl, 5- to 6-membered heteroaryl having 1 to 4 heteroatoms as ring vertices independently selected from N, O, and S, 5- to 6-membered heterocycloalkyl having 1 to 3 heteroatoms as ring vertices independently selected from N, O, and S, 6- to 10-membered bicyclic heterocyclyl having 1 to 4 heteroatoms as ring vertices independently selected from N, O, and S, 6- to 10-membered bridged heterocyclyl having 1 to 3 heteroatoms as ring vertices independently selected from N, O, and S, and 6- to 12-membered spiroheterocyclyl having 1 to 3 heteroatoms as ring vertices independently selected from N, O, and S, wherein Ar 1 is substituted with 0 to 3 R 3 ;

each R 3 is independently selected from the group consisting of C 1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4 haloalkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkyloxy, —X 2 —OH, —X 2 —O—C 1-4 alkyl, —C(O)—C 1-4 alkyl, and —X 2 -cyano; or two R 3 on adjacent ring vertices, combine to form a C 3-6 cycloalkyl, or two R 3 on the same ring vertex, combine to form oxo, wherein each X 2 is independently selected from a bond and C 1-4 alkylene;

Z is selected from the group consisting of:

(i) 4- to 6-membered heterocycloalkyl having 1 to 3 heteroatoms as ring vertices independently selected from N, O, and S, wherein S ring vertices are optionally oxidized to S(O) or S(O) 2 ;

(ii) C 5-8 bridged cycloalkyl;

(iii) C 6-12 spirocyclyl;

(iv) C 5-7 cycloalkyl substituted at adjacent ring vertices with moieties that combine to form a 5- or 6-membered heteroaryl having 1 to 3 heteroatoms as ring vertices independently selected from N, O, and S, thereby forming a fused ring system;

(v) 5- to 7-membered heterocycloalkyl having 1 to 3 heteroatoms as ring vertices independently selected from N, O, and S substituted at adjacent ring vertices with moieties that combine to form a 5- or 6-membered heteroaryl having 0 to 2 additional heteroatoms as ring vertices independently selected from N, O, and S, thereby forming a fused ring system;

(vi) 5- or 6-membered heteroaryl having 1 to 3 heteroatoms as ring vertices independently selected from N, O, and S, and is substituted at adjacent ring vertices with two moieties that combine to form a 5- to 6-membered saturated or partially unsaturated ring comprising 0 to 2 additional heteroatoms as ring vertices independently selected from the group consisting of N, O, and S, thereby forming a fused ring system;

(vii) C 5-7 bridged heterocyclyl having 1 to 3 heteroatoms as ring vertices independently selected from N, O, and S;

(viii) 6- to 12-membered spiroheterocyclyl having 1 to 3 heteroatoms as ring vertices independently selected from N, O, and S; and

(ix) 4- to 10-membered bicyclic heterocyclyl having 1 to 4 heteroatoms as ring vertices independently selected from N, O, and S,

wherein each Z is substituted with 0 to 3 R 4 substituents, each of which is independently selected from C 1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy, —X 3 —OH, C 3-6 cycloalkyl, C 3-6 cycloalkyloxy, —X 3 -cyano, —X 3 —O—C 1-4 alkyl, —X 3 —C(O)OH, —S(O)(NH)—C 1-4 alkyl, —S(O) 2 —C 1-4 alkyl, —C(O)—C 1-4 alkyl, and —X 4 -heterocycloalkyl comprising 4- to 6-ring members and 1 to 3 heteroatoms as ring vertices independently selected from N, O, and S; or two R 4 substituents are combined to form an oxo moiety,

wherein

each cycloalkyl is independently substituted with from 0 to 3 substituents independently selected from the group consisting of C 1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4 alkoxy, —X 3 —O—C 1-4 alkyl, —X 3 —C(O)OH, and —X 3 —OH;

each X 3 is independently selected from a bond and C 1-4 alkylene, and

each X 4 is independently selected from a bond, —O—, and C 1-4 alkylene;

or a pharmaceutically acceptable salt thereof.

2 - 3 . (canceled)

4 . The compound of claim 1 , having Formula (Ia)

or a pharmaceutically acceptable salt thereof.

5 . The compound of claim 1 , wherein Z is a 4-membered heterocycloalkyl substituted with 0 to 3 R 4 .

6 . The compound of claim 1 , wherein Z is a 5-membered heterocycloalkyl substituted with 0 to 3 R 4 .

7 . The compound of claim 1 , wherein Z is a 6-membered heterocycloalkyl substituted with 0 to 3 R 4 .

8 . The compound of claim 1 , wherein Z is a C 5-8 bridged cycloalkyl, substituted with 0 to 3 R 4 .

9 . The compound of to claim 1 , wherein Z is a C 6-12 spirocyclyl, substituted with 0 to 3 R 4 .

10 - 15 . (canceled)

16 . A compound of Formula (II)

wherein:

X 1 is selected from the group consisting of CH 2 and C 2-4 alkylene substituted with from 0 to 1 —OH;

ring A is selected from the group consisting of phenyl and a 5- to 10-membered heteroaryl having 1 to 3 heteroatoms as ring vertices independently selected from N, O, and S;

the subscripts m and n are each independently 0 or 1;

each R 1 and R 2 , when present, are each independently selected from C 1-4 alkyl, C 1-4 alkoxy, halo, C 1-4 haloalkyl, C 1-4 haloalkoxy, C 1-4 hydroxyalkyl, —C(O)OH, and cyano;

Ar 1 is selected from the group consisting of phenyl, 5- to 6-membered heteroaryl having 1 to 3 heteroatoms as ring vertices independently selected from N, O, and S, 5- to 6-membered heterocycloalkyl having 1 to 3 heteroatoms as ring vertices independently selected from N, O, and S, 6- to 10-membered bicyclic heterocyclyl having 1 to 4 heteroatoms as ring vertices independently selected from N, O, and S, 6- to 10-membered bridged heterocyclyl having 1 to 3 heteroatoms as ring vertices independently selected from N, O, and S, and 6- to 12-membered spiroheterocyclyl having 1 to 3 heteroatoms as ring vertices independently selected from N, O, and S, wherein Ar 1 is substituted with 0 to 3 R 3 ;

each R 3 is independently selected from the group consisting of C 1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4 haloalkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkyloxy, —X 2 —OH, —X 2 —O—C 1-4 alkyl, —C(O)—C 1-4 alkyl, and —X 2 -cyano; or two R 3 on adjacent ring vertices, combine to form a C 3-6 cycloalkyl, or two R 3 on the same ring vertex, combine to form oxo, wherein each X 2 is independently selected from a bond and C 1-4 alkylene;

Ar 2 is selected from the group consisting of phenyl, 5- to 10-membered heteroaryl having 1 to 3 heteroatoms as ring vertices independently selected from N, O, and S, and C 3-6 cycloalkyl,

wherein each Ar 2 is substituted with an R 4a substituent selected from the group consisting of —X 3 —OH, —X 3 —O—C 1-4 alkyl, C 3-6 cycloalkyl, —X 5 —C(O)OH, —C 2-4 alkylene-cyano, —S(O)(NH)—C 1-4 alkyl, —S(O) 2 —C 1-4 alkyl, and —X 4 -heterocycloalkyl comprising 4- to 6-ring members and 1 to 3 heteroatoms as ring vertices independently selected from N, O, and S wherein

each cycloalkyl is independently substituted with from 1 to 2 substituents independently selected from —X 3 —O—C 1-4 alkyl, —X 5 —C(O)OH and —X 3 —OH;

and wherein each Ar 2 is also substituted with 0 to 2 R 4 substituents each of which is independently selected from the group consisting of C 1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy, —X 5 —OH, C 3-6 cycloalkyl, —X 5 -cyano, and C 3-6 cycloalkyloxy;

each X 3 is independently C 1-4 alkylene;

each X 4 is selected from —O— and C 1-4 alkylene; and

each X 5 is independently selected from a bond and C 1-4 alkylene;

or a pharmaceutically acceptable salt thereof.

17 - 25 . (canceled)

26 . A compound of Formula (IV)

wherein

X 1 is selected from the group consisting of CH 2 and C 2-4 alkylene substituted with from 0 to 1 —OH;

ring A is selected from the group consisting of phenyl and a 5- to 10-membered heteroaryl having 1 to 4 heteroatoms as ring vertices independently selected from N, O, and S;

the subscripts m and n are each independently 0 or 1;

R 1 and R 2 , when present, are each independently selected from the group consisting of C 1-4 alkyl, C 1-4 alkoxy, halo, C 1-4 haloalkyl, C 1-4 haloalkoxy, C 1-4 hydroxyalkyl, —X a —O—C 3-6 cycaloalkyl, —C(O)OH, and cyano, wherein X a is independently selected from a bond and C 1-4 alkylene;

Ar 1 is selected from the group consisting of phenyl, 5- to 6-membered heteroaryl having 1 to 4 heteroatoms as ring vertices independently selected from N, O, and S, 5- to 6-membered heterocycloalkyl having 1 to 3 heteroatoms as ring vertices independently selected from N, O, and S, 6- to 10-membered bicyclic heterocyclyl having 1 to 4 heteroatoms as ring vertices independently selected from N, O, and S, 6- to 10-membered bridged heterocyclyl having 1 to 3 heteroatoms as ring vertices independently selected from N, O, and S, and 6- to 12-membered spiroheterocyclyl having 1 to 3 heteroatoms as ring vertices independently selected from N, O, and S, wherein Ar 1 is substituted with 0 to 3 R 3 ;

each R 3 is independently selected from the group consisting of C 1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4 haloalkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkyloxy, —X 2 —OH, —X 2 —O—C 1-4 alkyl, —C(O)—C 1-4 alkyl, and —X 2 -cyano; or two R 3 on adjacent ring vertices, combine to form a C 3-6 cycloalkyl, or two R 3 on the same ring vertex, combine to form oxo, wherein each X 2 is selected from a bond and C 1-4 alkylene; and

Z 1 is C 3-6 cycloalkyl substituted with 1 to 3 R 5 substituents,

wherein each R 5 is independently selected from —OH, cyano, C 1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4 alkoxy, and C 1-4 haloalkoxy;

or a pharmaceutically acceptable salt thereof.

27 - 35 . (canceled)

36 . The compound of claim 1 , wherein ring A is phenyl, pyridinyl, pyridazinyl, imidazolyl, pyrazolyl, triazolyl, imidazo[1,2-a]pyridinyl, [1,2,3]triazolo[1,5-a]pyridinyl, imidazo[1,5-a]pyridinyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,2-b]pyridinyl, pyrazolo[1,5-a]pyridinyl, [1,2,4]triazolo[1,5-a]pyridinyl, 1,6-naphthyridinyl, or 1,7-naphthyridinyl.

37 - 38 . (canceled)

39 . The compound of claim 1 , wherein ring A is pyridyl.

40 - 43 . (canceled)

44 . The compound of claim 1 , wherein Ar 1 is heteroaryl substituted with 0 to 3 R 3 .

45 . (canceled)

46 . The compound of claim 1 , wherein Ar 1 is pyridyl, substituted with 0 to 3 R 3 .

47 - 51 . (canceled)

52 . The compound of claim 1 , wherein R 1 and R 2 , when present, are each independently selected from the group consisting of C 1-4 alkyl, C 1-4 alkoxy, halo, and C 1-4 haloalkyl.

53 . (canceled)

54 . The compound of claim 1 , wherein each R 3 is independently selected from C 1-4 alkyl, halo, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy, and C 3-6 cycloalkyl, —X 2 —OH, and —X 2 -cyano.

55 - 63 . (canceled)

64 . A compound selected from those in Table 1.

65 . (canceled)

66 . A pharmaceutical composition comprising a compound of claim 1 , and at least one pharmaceutically acceptable excipient.

67 . A method for treating a disease characterized by overexpression of Polθ in a patient comprising administering to the patient a therapeutically effective amount of a compound of claim 1 .

68 . (canceled)

69 . A method of treating a homologous recombinant (HR) deficient cancer in a patient comprising administering to the patient a therapeutically effective amount of a compound of claim 1 .

70 . (canceled)

71 . A method for treating a cancer in a patient, wherein the cancer is characterized by a reduction or absence of BRCA gene expression, the absence of the BRAC gene, or reduced function of BRCA protein, comprising administering to the subject a therapeutically effective amount of a compound of claim 1 .

72 . The method of claim 71 , wherein the cancer is lymphoma, rhabdoid tumor, multiple myeloma, uterine cancer, gastric cancer, peripheral nervous system cancer, rhabdomyosarcoma, bone cancer, colorectal cancer, mesothelioma, breast cancer, ovarian cancer, lung cancer, fibroblast cancer, central nervous system cancer, urinary tract cancer, upper aerodigestive cancer, leukemia, kidney cancer, skin cancer, esophageal cancer, and pancreatic cancer.

73 - 77 . (canceled)